Absence of Glutathione Peroxidase 4 Affects Tumor Angiogenesis through Increased 12/15-Lipoxygenase Activity  by Schneider, Manuela et al.
Absence of Glutathione
Peroxidase 4 Affects Tumor
Angiogenesis through Increased
12/15-Lipoxygenase Activity1
Manuela Schneider*,†, Markus Wortmann*,
Pankaj Kumar Mandal†,
Warangkana Arpornchayanon*,‡,
Katharina Jannasch§, Frauke Alves§,
Sebastian Strieth‡, Marcus Conrad†,2
and Heike Beck*,2
*Walter Brendel Center of Experimental Medicine,
Ludwig-Maximilians-University, Munich, Germany;
†Institute of Clinical Molecular Biology and Tumor
Genetics, Helmholtz Zentrum München, German
Research Center for Environmental Health, Munich,
Germany; ‡Department of Otorhinolaryngology,
Ludwig-Maximilians-University, Munich, Germany;
§Department of Hematology and Oncology, University
Medicine Göttingen, Göttingen, Germany
Abstract
The selenoenzyme glutathione peroxidase 4 (GPx4) has been described to control specific cyclooxygenases (COXs)
and lipoxygenases (LOXs) that exert substantiated functions in tumor growth and angiogenesis. Therefore, we hy-
pothesized a putative regulatory role of GPx4 during tumor progression and created transformed murine embryonic
fibroblasts with inducible disruption of GPx4. GPx4 inactivation caused rapid cell death in vitro, which could be pre-
vented either by lipophilic antioxidants or by 12/15-LOX–specific inhibitors, but not by inhibitors targeting other LOX
isoforms or COX. Surprisingly, transformed GPx4+/− cells did not die when grown in Matrigel but gave rise to tumor
spheroids. Subcutaneous implantation of tumor cells into mice resulted in knockout tumors that were indistinguish-
able in volume and mass in comparison to wild-type tumors. However, further analysis revealed a strong vascular
phenotype. We observed an increase in microvessel density as well as a reduction in the number of large diameter
vessels covered by smooth muscle cells. This phenotype could be linked to increased 12/15-LOX activity that was
accompanied by an up-regulation of basic fibroblast growth factor and down-regulation of vascular endothelial growth
factor A protein expression. Indeed, pharmacological inhibition of 12/15-LOX successfully reversed the tumor pheno-
type and led to “normalized” vessel morphology. Thus, we conclude that GPx4, through controlling 12/15-LOX activity,
is an important regulator of tumor angiogenesis as well as vessel maturation.
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Introduction
The selenoenzyme glutathione peroxidase 4 (GPx4) was initially de-
scribed as an important intracellular antioxidant enzyme for the pro-
tection of membranes by its unique capacity to reduce phospholipid
hydroperoxides [1]. Later, GPx4 has been considered to be involved
in eicosanoid synthesis by controlling cyclooxygenase (COX) and
lipoxygenase (LOX) activities [2]. Because these enzymes require
basal amounts of lipid hydroperoxides for their activation [3,4], the
modulation of GPx4 activity should effectively influence COX and
LOX activities and thus eicosanoid synthesis. Indeed, aberrant arachi-
donic acid metabolism has been demonstrated to play a crucial role in
carcinogenesis and tumor angiogenesis [5]. Thus, pharmacological tar-
geting of GPx4, which in turn influences arachidonic acid metabo-
lism, can be considered as a promising strategy to interfere with the
tumor-host communication. Yet, it has remained obscure if there is
specificity of GPx4 toward distinct LOX and COX isoforms and if
an unbalanced regulation of distinct enzymes may influence tumor de-
velopment in vivo [6]. Our recent study using inducible inactivation
of GPx4 in cells and mice provided unequivocal evidence that GPx4
effectively prevents oxidative stress–induced cell death by specifically
controlling 12/15-LOX [7,8]. The impact of 12/15-LOX (or the
corresponding human ortholog 15-LOX-1) on carcinogenesis seems
quite complex, and its role in cancer development and progression is
controversially discussed [9]. 12/15-LOX shows increased expression
in normal tissues and benign lesions, but not in carcinomas of the blad-
der, breast, colon, lung, or prostate [10–14]. However, other studies
suggested that the 12/15-LOX product, 13-S-hydroxyoctadecadienoic
acid (13-HODE), enhances colon carcinogenesis [15]. Moreover, 13-
HODE has been shown to enhance cell proliferation and to potentiate
the mitogenic response to epidermal growth factor (EGF) in different
cell types such as BALB/c 3T3, Syrian hamster embryo (SHE) cells
[16], as well as human pancreatic adenocarcinomas [16,17]. In addition,
overexpression of the human ortholog 15-LOX-1 induces extracellular
signal–related kinase 1/2 phosphorylation, decreased p21 (cip/WAF1)
expression, and increased colon cancer growth [18]. Conversely, Kim
et al. [19] described an antiproliferative effect of 15-LOX-1 in colorec-
tal cancer cells associated with p53 phosphorylation. In line with these
results, Shureiqi et al. reported that 13-HODE induces apoptosis and
cell cycle arrest in colorectal cancer cells [20]. Studies analyzing the
biological relevance of 12/15-LOX in the vascular system seem similarly
inconsistent, and 12/15-LOX has been described to either promote or
inhibit neovascularization. Here, we hypothesize a putative regulatory
role of GPx4 during carcinogenesis. We strongly believe that our ge-
netic model of inducible GPx4 disruption is an ideal model to study
tumor progression and tumor angiogenesis in the context of modified
linoleic acid metabolism because GPx4 ablation specifically leads to
changes in 12/15-LOX activity.
Materials and Methods
Cell Line and Reagents
The 4-hydroxy-tamoxifen (TAM)–inducible GPx4 knockout mu-
rine embryonic fibroblasts (MEFs) were used as described by Seiler
et al. [7]. All cell culture reagents were purchased from Invitrogen
(Karlsruhe, Germany). MEFs were cultured at 37°C under 5% CO2
and 5% O2 in Dulbecco’s modified Eagle medium supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin. To maintain the viability of the cells after
induction of GPx4 deletion by adding TAM, cells were always main-
tained in the presence of (±)-6-hydroxy-2,5,7,8-tetramethylchromane-
2-carboxylic acid (Trolox; 1 μM, #56510; Sigma-Aldrich, Deisenhofen,
Germany), a water-soluble analog of α-tocopherol (see MTT Assay
for Cell Viability section). Tumor cells were harvested near conflu-
ence by brief trypsination in 0.25% trypsin/EDTA solution, washed
several times, and placed in sterile phosphate-buffered saline (PBS)
shortly before implantation. The pan-COX-inhibitor indomethacin
(I7378), the pan-LOX-inhibitor NDGA (N5023), and the 12/15-
LOX–specific inhibitors Baicalein (#465119) and PD146176 (P4620)
as well as 4-hydroxy-tamoxifen (H7904) were purchased from Sigma-
Aldrich. pBJ3Ω c-Myc and pUC EJ6.6 Ha-rasV12 were a kind gift from
Dr. Hartmut Land. Each time before performing an in vitro or in vivo
assay, GPx4-deleted cells were thoroughly washed with PBS to remove
Trolox. Furthermore, an aliquot of the cells was checked for GPx4 ex-
pression by quantitative polymerase chain reaction (PCR; see below).
As a second control, another aliquot was plated under normal cell culture
conditions without adding Trolox, and cell death was analyzed within the
next 48 to 72 hours (see below).
Transformation of Conditional GPx4-Deficient MEFs
For oncogenic transformation, GPx4-deficient MEFs were co-
transduced with c-Myc– and ha-rasV12–expressing lentiviruses. Soft agar
assays were conducted to select for transformed cells. The assay was per-
formed in 60-mm dishes (BD Falcon; Becton Dickinson, Heidelberg,
Germany) containing two layers of soft agar. The top and bottom layers
were 0.3% and 0.4% agarose, respectively, in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum. A total
of 2 × 104 of the c-Myc– and ha-ras–infected cells were added to the
top layer before pouring. Single-cell colonies were isolated approxi-
mately 2 to 3 weeks after culturing at 37°C and 5% CO2. Single-cell
clones were individually expanded, and GPx4 deletion was tested later
in each of the established cell lines by adding TAM (±Trolox) followed
by analysis of GPx4 expression (see quantitative reverse transcrip-
tion [RT]–PCR) and cell death, respectively (see MTT Assay for Cell
Viability section).
Immunoblot Analysis
Cell lysates and tumor tissue lysates, protein concentration determi-
nation, and immunoblot analysis of GPx4 were performed as described
previously [7]. Ha-rasV12 and c-Myc expression was confirmed using
anti–Ha-ras (#3965; Cell Signaling Technology, New England Bio-
laboratories, Frankfurt am Main, Germany) and anti–c-Myc antibodies
(sc-788; Santa Cruz Biotechnology, Heidelberg, Germany).
MTT Assay for Cell Viability
Cells were plated in 96-well plates at 1 × 104 cells per well and
incubated overnight. Cells were treated either with Trolox (a water-
soluble analog of α-tocopherol; #56510; Sigma-Aldrich), with the
pan-COX inhibitor indomethacin, the general LOX inhibitor NDGA
and the 12/15-LOX-specific inhibitors Baicalein and PD146176 for
72 hours at various concentrations. Then, 10 μl of 5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; M2003;
Sigma-Aldrich) in PBS was added to 100 μl of culture media. Plates
were incubated for 4 hours, and the formazan precipitate was redis-
solved in 200 μl of 0.04N HCl in isopropanol. The absorbance at
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540 nm was recorded using a Sunrise microplate absorbance reader
(Tecan, Crailsheim, Germany).
Three-dimensional BD Matrigel Assay
Three days before starting the assay, deletion of GPx4 was induced
by adding TAM to the cell culture medium. To ensure survival of the
cells, Trolox, which fully complements GPx4 deficiency in vitro (see
MTT Assay for Cell Viability section), was given as a supplement to
the medium.
Two types of frozen Matrigel (Matrigel as well as Growth Factor–
reduced Matrigel; #356234 and #35623; Becton Dickinson GmbH)
were thawed overnight at 4°C, and 200 μl of each undiluted Matrigel
was placed on 24-well plates and incubated for 1 hour at 37°C.
Thereafter, tGPx4 knockout as well as control cells were thoroughly
washed with PBS to remove Trolox. Cells were counted and 5 ×
104 cells each were reconstituted in 20 μl of culture medium ±
TAM. Finally, cells were plated on the BD Matrigel layer, coated with
200 μl of undiluted Matrigel, and incubated for an additional hour at
37°C. Normal cell culture medium ± TAM was added on the top layer.
In parallel, the same amount of wild-type and knockout cells was plated
on uncoated 24-well plates ± TAM, and GPx4 deletion was verified by
analyzing cell death within the next 48 to 72 hours.
The average number of spheroids per well was determined after
14 days of growth in both types of Matrigel. Pictures were taken from
triplicate experiments.
RNA Isolation, Reverse Transcription, and Quantitative RT-PCR
Cells were kept 72 hours under the conditions described above add-
ing either TAM and Trolox or Trolox alone to the cell culture medium.
Total RNA was extracted with the Qiagen RNA isolation kit (RNeasy
Mini Kit #74106; Qiagen, Hilden, Germany), and residual genomic
DNA was removed by the RNase-Free DNase Set (#79254; Qiagen).
RNA was reverse-transcribed into complementary DNA as described
before [21]. Real-time PCR was performed with Lightcycler in a
reaction volume of 10 μl using SYBR Green I (LC-FastStart DNA
MasterPlus, #03 515 885 001; Roche, Mannheim, Germany) according
to the manufacturer’s protocol. Primers were used at a final concentra-
tion of 0.5 μM each. An initial denaturation step at 95°C for 10 min-
utes was followed by 40 cycles of denaturation (95°C, 1 second),
annealing (65°C, 10 seconds), and extension (72°C, 20 seconds). Stan-
dard curve was prepared using four dilutions of complementary DNA
obtained from mouse embryonic fibroblasts. Relative messenger RNA
levels were normalized to β-actin messenger RNA levels in the same
samples. Primer sequences are as follows: GPx4 A forward (5′-GCA
ACC AGT TTG GGA GGC AGG AG-3′), GPx4 B reverse (5′-CCT
CCA TGG GAC CAT AGC GCT TC-3′); β-actin forward (5′-CTA
CGA GGG CTA TGC TCT CCC-3′) and reverse (5′-CCG GAC
TCATCG TAC TCC TGC-3′).
In Vivo Tumor Model
For in vivo implantation studies, cells were kept for at least 72 hours
under TAM and Trolox, and the knockout was verified as described
above. Before injecting the cells, cells were washed thoroughly with
PBS to remove TAM and Trolox. After cell counting, 5 × 106 c-Myc/
Ha-rasV12–transformed GPx4-deficient or GPx4-proficient MEFs di-
luted in 100 μl of sterile PBS were implanted subcutaneously into
the flanks of C57BL/6 or severe combined immunodeficient (SCID)
mice, respectively. Tumors were collected 16 days after implantation
(n = 8 mice per group). Tumor volume was calculated by caliber mea-
surement according to the following formula: V (mm3) = (length ×
width × high) × π/6. For the in vivo pharmacological studies, mice were
treated with Baicalein (1.5 mg/kg in Tween 20) orally every second day
beginning at day 3 after tumor cell implantation.
Mice were kept under standard conditions with food and water
ad libitum (ssniff, Soest, Germany). All animal experiments were per-
formed in compliance with the German Animal Welfare Law and
have been approved by the institutional committee on animal experi-
mentation and the government of Upper Bavaria.
Hematoxylin-Eosin Histology
Five-micrometer sections of 4% (wt./vol. in PBS) paraformaldehyde-
fixed and paraffin-embedded tumor material were stained as de-
scribed [22].
Immunohistochemistry and Image Analysis
Tumor tissue samples were snap frozen in liquid nitrogen and
stored at −80°C. Ten-micrometer frozen sections were prepared using
a cryotome (HM 560; Microm, Walldorf, Germany) and mounted on
poly-L-lysine–coated glass slides (Menzel, Braunschweig, Germany).
Immunostaining was performed using a phospho–histone H3 anti-
body (1:200; # 9701; Cell Signaling Technology, New England Bio-
laboratories) for proliferating cells, a CD31 antibody (1:800; BM 4086B;
Acris Antibodies, Hiddenhausen, Germany) for endothelial cells, an
α-smooth muscle cell antibody (1:200, A2547; Sigma-Aldrich) to
mark endothelial coverage by vascular smooth muscle cells/pericytes
and the ApopTag Peroxidase In Situ Apoptosis Detection Kit (S7100;
Serologicals Corporation, Millipore, Schwalbach, Germany) for the
detection of apoptotic nuclei according to the manufacturers’ recom-
mendations. Immunoperoxidase staining was performed using the
Vector ABC Kit and Vector DAB Kit (Vector Laboratories, Linaris,
Wertheim-Bettingen, Germany).
Quantification of Proliferation and Apoptosis
The number of proliferating or apoptotic cells, respectively, was de-
termined in a genotype-blinded fashion in 10 random microscopic
visual fields at 200-fold magnification and quantified using pixel-based
thresholds in a computer-assisted image analysis software (KS400 Im-
aging System; Carl Zeiss Vision, Hallbergmoos, Germany) defined as
positively stained area per total area.
Quantification of Blood Vessel Density
The number of total blood vessels was determined in a genotype-
blinded fashion by counting the number of blood vessels in 10 random
microscopic visual fields at 200-fold magnification. Blood vessel den-
sity, defined as percentage of CD31-positive staining per unit area, was
quantified using pixel-based thresholds in a computer-assisted image
analysis software (KS400 Imaging System; Carl Zeiss Vision).
Quantification of Pericyte-Covered Tumor Vessels
Tumor sections were double-stained with anti-CD31 antibody for
endothelial cells, and anti–α-smooth muscle actin (αSMA) antibodies
for smooth muscle cells/pericytes. The number of α-smooth muscle
cell–covered vessels was determined in a genotype-blinded fashion in
10 random microscopic visual fields at 200-fold magnification.
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In Vivo Fluorescence Microscopy
Experiments were performed in male C57BL/6 mice (8-10 weeks
old, 25-35 g, n = 4 mice per group). A dorsal skinfold chamber was
implanted under anesthesia (subcutaneous injection of 75 mg of ke-
tamine hydrochloride/25 mg xylazine per kilogram body weight) as
described [23]. Animals were allowed to recover from the chamber
implantation surgery for 2 to 3 days before tumor cells were inocu-
lated into the skinfold chamber preparation.
Before measurement of vessel diameter and vessel density at days
7, 10, and 14 after tumor cell implantation, animals were placed in a
polycarbonate tube and were injected intravenously with 0.1 ml of a
fluorescein isothiocyanate (FITC)–labeled dextran solution (5% in
0.9% NaCl, MW = 200,000, FD20; Sigma-Aldrich).
The chamber preparation was mounted on an individually designed
microscope stage (Axioplan; Zeiss, Jena, Germany), and tumor vascu-
larization was observed by using a 20× objective (LD acroplan; Zeiss).
Epi-illumination was achieved with a 100-W mercury lamp with a
fluorescence filter for FITC (excitation, 450-490 nm; emission, 515-
525 nm). Images of microvessels in five areas of the tumor were acquired
by using a CCD camera (AVC D7; Sony, Tokyo, Japan), displayed on a
video monitor and recorded on digital tapes by using a video recorder
(SVO-9500MD; Sony) for offline analysis.
Flat-Panel Volume Computed Tomography Imaging
Mice were imaged with flat-panel volume computed tomography
(fpVCT), a nonclinical volume computed tomography prototype (GE
Global Research, Niskayuna, NY) as described [24,25]. In brief, mice
were anesthetizedwith vaporized isoflurane at 0.8% to 1%concentration,
centered on the fpVCT gantry axis of rotation, and placed perpendicu-
larly to the z-axis of the system. At distinct time points, iodine-containing
contrast agent, 150 μl of Isovist 300 (Bayer-Schering, Berlin, Germany)
per mouse, was applied intravenously approximately 30 seconds before
scan, and for better demonstration of small blood vessels, the blood
pool agent eXia 160 (Binito Biomedical Inc, Ottawa, Canada) was ad-
ministered intravenously 90 seconds before each scan as described by
Jannasch et al. [25]. All data sets were acquired with the same protocol:
500 views per rotation, 4 seconds rotation time, 360 used detector rows,
tube voltage of 80 kilovolt (peak), and a current of 100 mA. A modi-
fied Feldkamp algorithm was used for image reconstruction resulting in
Figure 1. Inducible deletion of GPx4 in transformed cells leads to rapid cell death, which can be prevented by Trolox or 12/15-LOX inhibitors.
(A) MEFs isolated from conditional GPx4 knockout mice were transfected with a TAM-inducible GPx4 knockout system [7]. MERCreMER
(MER = mutated estrogen receptor) is retained in the cytosol. On addition of TAM, MERCreMER translocates to the nucleus where Cre-
mediated deletion of the floxed GPx4 alleles occurs. (B) Immunoblot analysis with a monoclonal antibody directed against murine GPx4
peptide shows strongly reduced GPx4 protein levels after TAM administration (upper panel). TAM-inducible GPx4 MEFs were transformed
with the oncogenes c-Myc and Ha-rasV12 using lentivirus-mediated gene transfer. The expression of both oncogenes was confirmed by
immunoblot analysis (lower panel). (C) TAM-induced cell death of GPx4 knockout MEFs can be prevented by Trolox or (D) by the general
LOX inhibitor NDGA and the 12/15-LOX specific inhibitors Baicalein and PD146176 but not by the general COX inhibitor indomethacin. Cell
viability was determined 72 hours after TAM treatment byMTT assay. Trolox, NDGA, Baicalein, or PD146176 treatment caused a statistically
significant increase in cell viability compared with cell viability in nontreated GPx4-deleted cells.
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isotropic high-resolution volume data sets (512 × 512 matrix, with an
isotropic voxel size of approximately 100 μm). For tumor segmentation
and volume estimation, data sets were analyzed with voxtools 3.0.64
Advantage Workstation 4.2 (GE Healthcare, UK).
Enzyme-Linked Immunosorbent Assay for Vascular
Endothelial Growth Factor A, Placenta Growth Factor,
and Basic Fibroblast Growth Factor
Lysates from GPx4 knockout and control tumors as well as cell cul-
ture supernatants from both types of cells were prepared, and enzyme-
linked immunosorbent assays (ELISAs) for vascular endothelial growth
factor (VEGF; MMV00), placenta growth factor (PlGF; MP200),
and basic fibroblast growth factor (bFGF, DFB50; all purchased from
R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany) were per-
formed as described in the accompanying Quantikine ELISA protocols.
All ELISA results were read on a Sunrise microplate absorbance reader
(Tecan) at an absorbance of 450 nm, with wavelength correction at
550 nm, and calculated according to the manufacturers’ recommenda-
tions. Total protein concentrations of tumor homogenates and super-
natants were measured with the BCA Protein Assay Kit (#23227;
Pierce, Fisher Scientific GmbH, Schwerte, Germany).
Statistical Analysis
Statistical analysis was performed using SigmaStat software. The
statistical significance of the results was tested by Student’s t test. P <
.05 was considered statistically significant. Results were expressed as
mean ± SD.
Results
Transformation of Inducible GPx4 Knockout MEFs with the
Oncogenes c-Myc and Ha-rasV12
To investigate the impact of GPx4 depletion on tumorigenesis,
we took advantage of our recently established TAM-inducible GPx4
knockout fibroblasts (Figure 1A) [7]. These cells were cotransduced
with c-Myc– or Ha-rasV12–expressing lentiviruses. To establish stably
transformed cell lines, colony formation assays were performed, which
allowed to isolate single-cell colonies after 2 to 3 weeks of growth in
soft agar. Single-cell clones were individually expanded, and the ex-
pression of both oncogenes c-Myc and Ha-rasV12 was confirmed by im-
munoblot analysis (Figure 1B). All the following experiments were
performed using the c-Myc– or Ha-rasV12–transformed TAM-inducible
GPx4 knockout fibroblasts (tGPx4).
As shown previously, inducible depletion of GPx4 in nontransformed
MEFs caused rapid cell death within 48 hours after knockout induc-
tion, which could be prevented either by α-tocopherol or by 12/15-
LOX–specific inhibitors. Water-soluble antioxidants and 5-LOX– and
COX-specific inhibitors were shown to be ineffective in preventing cell
death [7]. To address whether transformed GPx4 knockout cells behave
differently with respect to cell proliferation and cell survival, the knock-
out was induced by TAM in the presence and absence of Trolox, an
α-tocopherol analog, and various LOX and COX inhibitors. Cell via-
bility was determined by MTT assay 72 hours after TAM treatment.
As illustrated in Figure 1, C and D, cell death of transformed GPx4
knockout cells could be prevented by Trolox, NDGA, Baicalein, and
the 12/15-LOX–specific inhibitor PD146176, but not by the COX
inhibitor indomethacin. Hence, in terms of cell viability in vitro, trans-
formed GPx4-null cells do not substantially deviate from the non-
transformed parental cell lines.
tGPx4-Deficient MEFs Form Tumor Spheroids in
Three-dimensional Extracellular Matrix
One characteristic of tumor cells is their ability to form three-
dimensional structures in reconstituted extracellular matrix (ECM)
such as BD Matrigel, a solubilized basement membrane preparation
extracted from the Engelbreth-Holm-Swarm mouse sarcoma [26].
Interaction of tumor cells with the ECM is thought to be a critical
event in controlling angiogenesis and tumor growth. To compare the
(tumor cell) behavior of GPx4-deficient and -proficient transformed
MEFs, cells were plated in between two layers of BD Matrigel to
obtain a three-dimensional culture assay.
Unexpectedly, tGPx4-null cells embedded in three-dimensional BD
Matrigel survived and indeed formed tumor cell colonies (Figure 2B).
Such colonies were similar in appearance and number (17.53 ± 6.51;
Figure 2, B and E) compared with the colonies formed by control cells
(17.60 ± 2.67; Figure 2, A and E). To test whether survival of GPx4-
deficient MEFs was dependent on the growth factor content of BD
Figure 2. GPx4 knockoutMEFs survive in BDMatrigel. TAM-induced
GPx4 knockout MEFs and uninduced control cells were either em-
bedded in BD Matrigel (A and B) or plated on normal culture dishes
(C and D). After 14 days in BDMatrigel, GPx4 knockout cells formed
tumor spheroids (B and E) that were comparable in appearance and
number to tumor spheroids formed by control cells (A and E). Similar
results were obtained when tumor cells were embedded in Growth
Factor–reduced Matrigel (F). In contrast, GPx4 knockout cells plated
on normal dishes died within 48 hours (D).
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Matrigel, cell survival and colony formation were tested in parallel in
BD Growth Factor–reduced Matrigel. No significant difference in
the number of colonies could be found between the two types cells,
although the overall number of colonies was reduced under the condi-
tions of limited growth factor availability (12.77 ± 7.07 control colonies
vs 13 ± 5.24 knockout colonies; Figure 2F). In contrast, a strong reduc-
tion in cell number of tGPx4-null cells seeded on uncoated plates was
observed after 48 hours (Figure 2D), whereas wild-type cells survived
(Figure 2C).
Transformed GPx4-Deficient MEFs Form Tumors with
Higher Mitotic Activity but Also an Increased Number
of Apoptotic Cells
Because transformed GPx4-deficient cells died under normal cell
culture conditions, but survived and formed colonies when plated in
ECM-like BD Matrigel, we asked whether tGPx4-deficient cells gen-
erate tumors in vivo. To this end, tGPx4-deficient MEFs and the cor-
responding noninduced control cells were subcutaneously injected into
the flanks of C57BL/6 mice. Tumor growth was monitored every sec-
ond day, and tumors were harvested and analyzed at day 16 after tumor
cell injection. Surprisingly, GPx4-deficient and GPx4 control tumors
revealed no significant difference with regard to morphologic appearance
(Figure 3, A and D), tumor volume (1399.49 ± 767.21 vs 1427.86 ±
1088.49 mm3; Figure 3E ) and tumor mass (1.77 ± 0.72 vs 1.62 ±
1.58 g; Figure 3F). To exclude the possibility that tumors arose from
noninduced wild-type cells in the TAM-treated group, GPx4 expression
in tumor tissue was analyzed by immunoblot analysis with a GPx4-
specific antibody. As illustrated in Figure 3G , tumor lysates showed
strongly reduced GPx4 expression, indicating that tumors were indeed
derived from tGPx4-null cells.
Interestingly, immunohistochemical staining using the proliferation
marker phospho–histone H3 revealed an increase in the proliferation
rate of GPx4-deficient tumors (8.08 ± 2.07%) compared with con-
trol tumors (6.82 ± 2.08%; Figure 3, H–J ). Whereas tumors from
both groups displayed regions of necrosis, the portion of apoptotic
cells was higher in GPx4-deficient tumors (3.85 ± 0.78%) than in
control tumors (2.30 ± 1.22%) as detected by TUNEL staining (Fig-
ure 3, K –M).
Figure 3. GPx4-deficient transformed MEFs are capable to form tumors in vivo (A–D) and display elevated tumor proliferation and apop-
tosis (H–M). (A–F) c-Myc/Ha-rasV12–transformed GPx4-deficient MEFs were implanted subcutaneously into C57BL/6 mice. Tumors were
collected 16 days after implantation. Control and GPx4 knockout tumors did not show a significant difference in the macroscopic ap-
pearance (A–D), tumor volume (E), and tumor mass (F). (G) Deletion of GPx4 in the tumors was confirmed by immunoblot analysis. (H–J)
Immunohistologic analysis revealed a higher proliferation rate in GPx4 knockout tumors (I) compared with control tumors (H) using PH3
antibody as marker for proliferation. (K–M) TUNEL staining demonstrated more apoptotic cells in tumors derived from GPx4-deficient
tumor cells (L) compared with control tumors (M).
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To quantitate the precise tumor growth and progression over time in
a noninvasive fashion, we applied the high-resolution imaging tech-
nique, fpVCT. By virtual isolation of the tumor from the acquired iso-
tropic high-resolution fpVCT data sets, tumor volumes were calculated
automatically by considering all three dimensions, allowing the genera-
tion of precise growth kinetics for each tumor over time. Single fpVCT
scans of the entire mice after application of an iodine-containing con-
trast agent were performed three times per week beginning at day 3 after
tumor cell inoculation. In addition, at day 7 and day 14 after tumor
cell implantation, we applied the blood pool contrast agent eXia 160
to illustrate the intratumoral vascular network as well as the vessel re-
cruitment from the host in response to the developing tumor. Evalua-
tion of GPx4-deficient tumors and control tumors over time by fpVCT
imaging yielded no differences in tumor size and progression. Further-
more, contrast medium–containing blood vessels with sizes greater than
150 μm in diameter around and within the tumors were determined.
The observed recruitment of host vessels by the tumors as well as the
characteristics of large diameter tumor vessels was comparable within
the two groups (Figure 4, A–D).
Increased Number of Microvessels in GPx4-Deficient Tumors
GPx4-deficient tumors displayed a higher rate of apoptotic cells,
nevertheless an increase in tumor cell proliferation. Therefore, no signifi-
cant alterations about tumor size, tumor weight, or growth rate could
be determined between GPx4-deficient tumors and control tumors.
In the next step, we performed CD31 immunostaining to evaluate
tumor vascularization. Analysis of serial sections for the CD31-positive
area demonstrated amarkedly increased number of small microvessels in
GPx4-deficient tumors (total vessel number, 364 ± 119.21), whereas
control tumors displayed decreased total vessel numbers (279.73 ±
83.79; Figure 5, A–D). However, it is noteworthy that, in control
tumors, the mean vessel area was clearly augmented compared with
GPx4 knockout tumors (mean ±SEM: 100.26 ± 10.35 vs 83.94 ±
12.69 μm2).
To analyze the density of effectively perfused tumor vessels in vivo,
tGPx4-deficient MEFs and control cells were implanted into the dorsal
skinfold chamber. Tumor cells were implanted 3 days after chamber
preparation, and in vivo fluorescence microscopy was performed at days
7, 10, and 14 after intravenous administration of FITC-dextran, respec-
tively. At days 7 and 10, no differences were observed in vessel diameter
and vessel density between GPx4-deficient and control tumors. How-
ever, at day 14, GPx4-null tumors showed a significantly higher func-
tional microcapillary density (262.96 ± 13.72) than control tumors
(202.26 ± 13.97; Figure 5, E–G), whereas control tumors had a signifi-
cantly increased tumor vessel diameter and caliber size (15.93 ± 0.60 vs
9.95 ± 0.47; Figure 5, E , F, and H ).
Decreased Number of αSMA-Covered Vessels
Tumor vessels were also characterized with respect to smooth mus-
cle cell/pericyte coverage by staining tumor sections with anti-CD31
and anti-αSMA antibodies; smooth muscle cell–positive vessels were
defined as CD31-positive structures associated with αSMA-positive
cells. Analysis of double-stained sections revealed a statistically sig-
nificant reduction in αSMA-positive vessels in GPx4 knockout tumors
when compared with control tumors (7.21 ± 1.81 vs 12.25 ± 0.76;
Figure 6, A–C).
VEGF-A, PlGF, and bFGF Levels of Tumors Derived from
tGPx4 Deficient Cells Were Similar to Control Tumors
Because GPx4 knockout tumors displayed a higher microvessel den-
sity that was associated with poor mural cell coverage, we wondered if
this might be due to an increased endothelial growth factor production
by GPx4 knockout tumors. Therefore, we quantified the amount of
VEGF-A, PlGF, and bFGF in tumor tissue lysates. Surprisingly, all en-
dothelial growth factor levels obtained from control tumors (VEGF-A,
479.61 ± 220.55 pg/ml; PlGF, 221.41 ± 151.27 ng/μg; bFGF, 272.63 ±
125.33 pg/μg) did not differ from the values obtained from GPx4
knockout tumors (VEGF-A, 555.63 ± 432.29 pg/μg; PlGF, 257.04 ±
Figure 4. In vivo imaging by fpVCT showed no significant alterations for GPx4-null tumors. SCID mice with tumors derived from either
GPx4-knockout cells or control cells were scanned over time using fpVCT in combination with the blood pool agent eXia 160. Repre-
sentative pictures from fpVCT data sets show that 7 days after implantation of tumor cells, tumors with comparable volumes formed in
both groups (A and C), whereas vessels could not be detected (B and D); red circles indicate tumor localization. Likewise, at the end of
the experiment, 14 days after tumor cell implantation, there were no differences in tumor volume and tumor vascularization between the
two groups. Note that the tumors of both groups showed similar vessel recruitment (arrows). Scale bars, 10 mm.
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83.82 ng/μg; bFGF, 233.03 ± 67.26 pg/μg). Because the SD in tumor
tissue samples was high, we also analyzed cell culture supernatants after
induction of GPx4 deletion (see below).
Increased bFGF and Decreased VEGF-A Levels in
Supernatants of GPx4-Deleted tMEFs
Quantification of VEGF-A, PlGF, and bFGF levels in supernatants
of GPx4-deleted tMEFs and control cells revealed a decrease inVEGF-A
protein expression levels (729.4 ± 29.38 pg/μg in control super-
natants vs 204.8 ± 6.13 pg/μg in GPx4 knockout supernatants), no
change in the levels of PlGF (2.49 ± 1.29 ng/μg in control vs 2.13 ±
0.76 ng/μg in GPx4 knockout supernatants), as well as a strong increase
in bFGF expression levels (14.6 ± 6.37 pg/μg in control vs 38.4 ±
8.66 pg/μg in GPx4 knockout supernatants). The increase of bFGF
is in accordance with data from the literature describing that the 12/
15-LOX product 13-HODE is an inducer of bFGF [27].
Baicalein Treatment of Tumor-Bearing Mice Reverses the
Vascular Alterations in GPx4-Deficient Tumors
Baicalein, a specific LOX inhibitor, was originally described as an
inhibitor of platelet-type 12-LOX, but later also reported to inhibit
human 15-LOX [28]. Moreover, Baicalein has already been success-
fully used for treating neurological disorders in mice [29,30]. Because
cell death of tGPx4 knockout cells could be prevented by Baicalein
in vitro, we sought to address whether the effects of GPx4 disruption
and perturbed 12/15-LOX activity might be reverted by Baicalein ad-
ministration in vivo. For this reason, GPx4 knockout and GPx4 con-
trol tumor-bearing mice were treated daily by intraperitoneal injections
of Baicalein. Immunohistologic analyses of Baicalein-treated tumor tis-
sue revealed a clear reduction in microvessel density (untreated GPx4
knockout tumors 8.40 ± 0.45% vs treated knockout tumors 6.54 ±
0.85%; Figure 7, A–C), which was accompanied by an increase in tumor
vessel diameters and mural cell coverage evaluated by αSMA-positive
vessels (untreated GPx4 knockout tumors 7.21 ± 1.81 vs treated knock-
out tumors 9.22 ± 2.55; Figure 7D). Tumor vessel density and smooth
muscle cell/pericyte coverage in Baicalein-treated control tumors revealed
no difference compared with the untreated control group (tumor vessel
Figure 5. Altered tumor vascularization in GPx4-null tumors com-
pared with control tumors. (A–D) Immunohistologic evaluation of
CD31-stained tumor sections revealed higher vessel density, in
particular more microvessels in GPx4 knockout tumors. (E–H) For
analysis of functional vascular density and vessel diameter, GPx4-
deficient cells were implanted into the dorsal skinfold chamber
preparations in mice. The microvessel density in knockout tumors
is significantly increased (E–G). However, newly formed vessels
had thinner diameter and markedly reduced vessel lumina in con-
trast to control tumors (E, F, and H).
Figure 6. Vessels of GPx4-null tumors show diminished pericyte
coverage. To further analyze vessel morphology, double staining
for CD31 and αSMA was performed on tumor sections (A and
B). We observed a reduced number of pericyte covered vessels
in GPx4 knockout tumors when compared with control tumors (C).
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density 8.79 ± 0.29% in untreated control tumors vs tumor vessel den-
sity 8.40 ± 0.42% in Baicalein-treated control tumors).
Discussion
Numerous studies focusing on the relationship between polyunsaturated
fatty acid metabolism and carcinogenesis have identified novel promis-
ing compounds targeting COX and LOX activities for anticancer thera-
pies [5,31]. Our recent findings, which identified GPx4 as an important
regulator of LOX-catalyzed arachidonic and linoleic acid metabolism by
specifically keeping 12/15-LOX activity on a low level [7], prompted us to
investigate the function ofGPx4 in tumorigenesis and tumor angiogenesis.
Therefore, we transformed TAM-inducible GPx4 knockout MEFs with
the oncogenes c-Myc andHa-rasV12. Like in the nontransformed parental
cell line, inducible GPx4 disruption caused massive cell death in vitro,
which could be prevented by lipophilic antioxidants such as Trolox as well
as by broad-range LOX inhibitors or 12/15-LOX–specific inhibitors.
Contrary to our expectations tGPx4-deficient cells survived when em-
bedded into BDMatrigel as well as into Growth Factor–reducedMatrigel
and formed three-dimensional “tumor spheroids,” which were compa-
rable to spheroids formed by tGPx4 wild-type cells. When implanted
subcutaneously into mice, tGPx4-deficient cells formed tumors that
were indistinguishable from wild-type tumors regarding tumor mass or
volume. However, further analysis revealed a strong vascular phenotype.
Tumors derived from tGPx4-deficient cells displayed more micro-
vessels. This phenotype was combined with a reduced number of large
diameter vessels as well as a reduction of endothelial tubes covered by
smooth muscle cells. Because overexpression of 15-LOX-1 in human
prostate cancer cell line PC-3 led to high levels of VEGF-A secretion
and therefore enhanced tumor angiogenesis [32], we were interested to
analyze whether GPx4-deficient tumors also produce higher levels of
VEGF-A. Interestingly, elevated 12/15-LOX activity in tGPx4 cells
did not result in increased VEGF-A protein levels in tumor tissues.
In addition, neither PlGF nor bFGF protein expression levels were in-
creased in vivo. However, analysis of cell supernatants derived from
GPx4-deficient and -proficient tMEFs revealed even a decrease of
VEGF-A protein expression levels and, at the same time, an increase in
bFGF expression levels. The increase of bFGF protein expression levels is
in accordance with previous data, showing that the 12/15-LOX product
13-HODE can induce this proangiogenic growth factor. Altogether,
results from various studies investigating the biological relevance of 12/
15-LOX in the vascular system seem rather inconsistent. 12/15-LOX
expression and function have been extensively studied in endothelial
cells, smooth muscle cells, and atherosclerotic animal models, where it
was shown to play a role in vascular remodeling as well as in the progres-
sion of atherosclerotic lesions [33,34]. Conversely, tumor studies demon-
strated that the enzyme and its metabolites can either promote or inhibit
neovascularization. For example, tumor formation and angiogenesis were
inhibited in transgenic mice overexpressing 15-LOX-1 in endothelial
cells [35]. In line with these data, Viita et al. [36] showed antiangiogenic
action of 15-LOX-1 in a model of hindlimb ischemia. Here, 15-LOX-1
significantly decreased all angiogenic effects induced by VEGF-A and
PlGF, including capillary perfusion, vascular permeability, vasodilatation,
and increase in capillary number.
One explanation for such inconsistent observations is that 12/
15-LOX overexpression might not necessarily result in an increased
activity of the enzyme. However, our genetic model of GPx4 ablation
leads to increased 12/15-LOX activity, and application of specific 12/
15-LOX inhibitors specifically prevents cell death in vitro. Interestingly,
no up-regulation of 12/15-LOX RNA or protein can be observed after
GPx4 deletion. A second explanation might be that various tumor
cell types might behave in a different way when exposed to altered
12/15-LOX activity.
By treating our GPx4-deprived tumor-bearing mice with the broad-
range LOX inhibitor Baicalein, we could successfully reverse the vascu-
lar alterations. Thus, we conclude that GPx4 through controlling 12/
15-LOX activity is an important regulator of tumor angiogenesis as well
as vessel maturation. Second, modulating 12/15-LOX activity through
GPx4 might be an interesting way to reshape tumor vessels.
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